Genetically informed prioritization of immune checkpoint–associated genes in head and neck cancer highlights HGF and AKT1
Immune checkpoint inhibitors are used to treat head and neck cancer (HNC), but clinical responses vary, and systematic genetic evaluation is needed to prioritize candidate susceptibility genes. We applied summary-data-based Mendelian randomization (SMR) and HEIDI testing to screen 624 immune checkpoint–related genes, i...